Cytomegalovirus microRNAs level determination in kidney recipients post transplantation

Afsoon Afshari1, Ramin Yaghobi2* and Mehdi Golshan2

Abstract

Background: Human cytomegalovirus (CMV) can establish a latent infection with periodic or sporadic reactivation after the first infection happens. Primary and recurrent infection, results in different problems in patients with impaired or immature immune systems, such as kidney transplant recipients (KTRs). MicroRNAs (miRNAs, miRs) are important regulatory molecules in the outcome of CMV-infected KTRs. Therefore, in this study the expression level of CMV miRNAs were evaluated in active vs. latent CMV infected KTRs.

Methods: Expression of viral miRNAs were studied in 61 KTRs which were divided into 30 active CMV and 31 latent CMV infected individuals. In order to study the expression level of selected miRNAs, SYBR Green Real-time PCR technique was exploited. Also, mature miRNAs expression level that were produced from one precursor, studied both in active and latent situations.

Results: Among studied miRNAs' expression level, CMV miR-UL112-3p/5p, -UL22A-3p/5p, -US25-1-5p, -US25-2-3p/5p, -UL36-3p/5p and -UL70-3p showed significant increase in active CMV infected KTRs in comparison to latent ones. The ROC curve analysis results for miR-UL112-3p, -UL22A-3p, -US25-2-3p, -UL36-3p and -UL70-3p showed significant difference between two studied patient groups.

Conclusion: This study revealed an extremely high expression level in CMV miR-UL112-3p/5p, -UL22A-3p/5p, -US25-1-5p, -US25-2-3p/5p, -UL36-3p and -UL70-3p in active CMV infected KTRs in comparison to latent ones. Further studies might help in finding the capability of miRNAs to differentiate active from latent stage of CMV infection in KTRs.

Keywords: Cytomegalovirus, Transplant, Kidney, MicroRNA

Introduction

Human cytomegalovirus (CMV) is a member of the Beta-herpesvirinae subfamily that discovered in the 1950s [1], which infects up to 60–100% of people in adulthood. This infection might appear after transplantation especially, up to 100 days post kidney transplantation [2]. Kidney transplant recipients (KTRs) have an increased susceptibility to opportunistic infections that might cause a rise in the risk of acute rejection episodes, decrease in graft survival, higher incidence of chronic allograft nephropathy and decrease in the patient survival rate [3, 4]. After detection and studying the regulatory capacities of microRNAs (miRNAs, miRs) of CMV, it seems conceivable that the virus might encode miRNAs for regulating the gene expression pattern in itself and host during productive replication in order to successfully infect, replicate, and stabilize in different cell types [5].

*Correspondence: rayaviro@yahoo.com

1 Shiraz Transplant Research Center, Shiraz University of Medical Sciences, Shiraz, Iran

Full list of author information is available at the end of the article
MiRNAs are a class of 19–22 nucleotide noncoding RNAs that have regulatory roles in all classes of metazoans through modulating gene expression during numerous biological processes [6, 7]. CMV is known to have evolved effective immune evasion strategies [8] and CMV-encoded miRNAs have effective immune evasion policies in manipulating the immune responses, which function in interspecies regulation involving viral miRNAs and host genes [9, 10].

The elevation of some miRNA's expression during latent phase in herpesviruses, produce a nonimmunogenic way for preparing a stable microenvironment suitable for latency [11]. However, expression of CMV miRNAs has been characterized mainly during lytic infection and merely been evaluated during latency either in vivo or in experimental cell culture latency models [12].

The variation in miRNAs' expression pattern is detected in some infectious diseases [13] that turn them to be promising biomarker candidates especially in viral infections. Circulating CMV encoded miRNAs have been considered as diagnostic and discriminative biomarkers in various diseases and their physiological and pathophysiological effects on disease development and progression have been confirmed lately [13, 14]. miR-UL112-3p has been elevated in cardiovascular diseases [14], hypertension and diabetes and glioblastoma multiforme [15], congenital CMV infection [16]. The importance of miR-US25-1-5p as biomarker is discussed in atherosclerosis and congenital CMV infection. Finally, miR-US33-5p have been traced in acute aortic dissection and miR-UL70-3p and miR-US4-5p in glioblastoma multiforme and in hepatitis B, respectively [16].

Currently, CMV infection has been known a serious complication in both hematopoietic stem cell (HSC) and solid organ transplanted (SOT) patients [17]. Some studies are certain about the ability of this CMV miRNA in prediction of replication and/or recurrence of infection specifically in immunocompromised transplanted patients [16].

In view of the CMV-miRNAs role in various situation during viral reactivation in transplanted patients and considering the fact that CMV primary infection and reactivation causes serious problems in KTRs, investigating the CMV-miRNAs expression level in these patients is helpful in handling and understanding the CMV infection outcomes. Therefore, in this study the expression level of CMV miRNAs were evaluated in active vs. latent CMV infected KTRs.

**Materials and methods**

**Patients and samples**

In this case–control study, 61 kidney transplant patients admitted to Namazi Hospital, Shiraz University of Medical Sciences, Iran, enrolled during 2018–2020. Five ml of EDTA-treated blood samples were collected from each patient in the first week post-transplantations and total PBMCs were extracted from each sample for further analysis. All patients were seropositive for HCMV infection and received anti-HCMV prophylaxis regimen on time transplantation. Patients were divided into two groups based on result of HCMV quantitative Real-time PCR method. Active CMV infected group consists of 30 patients with a positive (more than 10^4 copy/ml of viral DNA) result and latent group included 31 patients with a negative. This study was approved by the Ethical Committee of Shiraz University of Medical Sciences and also all the used protocols were in conformation with the ethical guidelines of Helsinki Declaration. 30 healthy control samples also were included. The demographical data related to study groups is presented in Additional file 1: Table S1.

All patients were given the same routine regimens of immunosuppressive drugs which consisted of tacrolimus or cyclosporine with mycophenolate mofetil and steroids. The blood level of 200 mg/ml was considered as the therapeutic target for cyclosporin A (CsA; 5 mg/kg/d) or 10 mg/ml of tacrolimus. Donors were selected based on ABO blood group compatibility. HLA matching is performed as a routine procedure for kidney transplanted patients. The including patients were older than 19 years old and all of the patients were tested for other viral infections such as HIV, HSV, HCV, HBV and EBV. The selected samples were negative for mentioned viral infections. Patients showing graft rejecting were excluded from the study. All the samples which composed the active CMV infected group were gathered before starting the anti-viral drugs.

**CMV taq-man real-time PCR**

Invisorb Spin Virus DNA Mini Kit (Invitek, Birkenfeld, Germany) was used for CMV-DNA extraction from plasma of all samples according to the manufacturer's instruction. The load of CMV-DNA was determined by using Gensig real-time PCR kit (Primer Design Ltd TM, Advanced kit, United Kingdom). The reaction mix was modified to 20 µl total volume consist of: 500 ng of CMV-DNA, 10 µl of precision TM Master Mix, 1 µl of primers and probe which glycoprotein B (gB) was their target, 1 µl of primers and probe that target the internal control (IC) gene (Applied Biosystems, Grand Island, NY, USA) and finally 3 µl nuclease free water was added. The thermal cycling program used for Step One Plus Real-time PCR thermocycler (Applied Biosystems, Grand Island, NY, USA) was as follow: 95 °C/10 min/1cycle, followed by 95 °C/5 s and then 60 °C/60 s for 50 cycles. This
assay was sensitive enough to detect as few as 10 copies of CMV genome/ml of samples.

The copy number of viral DNA was calculated and the patients were divided according the copy number of CMV-DNA. Samples that have more than $10 \times 10^3$ copy/ml were considered to have active viral infection.

**Molecular assays**

**RNA isolation and cDNA synthesis**

Total RNA of all samples were extracted from buffy coats using Trizol kit (RiboEx, Korea), with modified protocol. Purity and integrity of extracted RNA was determined by reading 260/280 nm optical density and electrophoresis of RNA on 1% agarose gel.

CDNA synthesis was performed by using a two-step designed procedure. In this procedure universal stem-loop primer (USTLP) is used for cDNA synthesis of all miRNAs. Therefore, in this process in the first step 1 µl dNTP (10 mM), 1 µl USTLP (10 pM), and extracted RNA (100 ng) is mixed in DEPC water until it reaches 10 µl. This mix is heated for 2 min in 65 °C. Then the mix is put on ice for 5 min. The second mix which is composed of 0.5 µl reverse transcriptase enzyme (Takara, Japan) and 2 µl of its 10 × buffer is reached to 10 µl by DEPC water and is added to the first mix. The whole mix is put in 50 °C for one hour for cDNA synthesis accomplished.

**SYBR green real-time PCR**

For Real-time mix SYBR Green Premix (Ex Taq, Takara, Otsa, Shiga, Japan) were used. The mRNA expression level of 12 miRNAs and control gene (U6) was measured using designed primers. The primer sequences, cycling conditions of RNA on 1% agarose gel.

**Statistical analysis**

Livak method ($2^{-\Delta \Delta C_t}$) was applied to evaluate the expression level of understudy genes in both active and latent CMV infected patients. Statistical analysis was performed by SPSS software ver.24 (SPSS, Chicago, IL, USA) including: non-parametric tests (Mann-Whitney U test for studying the $p$ value between two study groups, and k independent tests for studying the $p$ value between more than two study groups). GraphPad Prism 8 (GraphPad Software, Inc., San Diego, CA, USA) was used to design graphs and calculate the statistical tests. Two-sided Spearman correlation analysis was used to determine the association between miRs arisen from one precursor. Finally, $p \leq 0.05$ was determined as statistical significance.

**Results**

The demographic data of studied active versus latent CMV infected groups and controls is presented in Additional file 1: Table S1. Comparing the viral miRNAs gene expression in active versus latent CMV infected patients and control studied groups, showed that most of the CMV miRNAs had a significant increase in active CMV infected KTRs in comparison to latent ones and controls (Fig. 1A). Only miR-US25-1-3p and miR-UL148D had different expression patterns and their maximum expression level is found but not significantly in latent CMV infected group. Furthermore, the expression level of miR-UL22A-3p was decreased in latent CMV infected group in comparison to controls (Fig. 1A). The expression level of all tested miRNAs was compared with each other in latent CMV infected group (Fig. 1B). It is showed that miR-US36-3p/5p and miR-US25-2-5p has the most expression level in comparison to all other evaluated miRNAs in latent CMV infected patients. The expression level of miRNAs was also compared with each other in active CMV infected group. miR-UL112-5p, miR-US25-2-5p, and miR-UL36-5p has the most expression level in comparison to other miRNAs (Fig. 1C). miR-UL112-3p has several viral and cellular targets. Remarkably, this suggests that single viral miRNAs have the capability to target both cellular and viral gene expression [6] (Additional file 1: Table S5). miR-UL112-3p have the potential of being considered as a differentiating marker between latent CMV infected and active groups of patients.

Furthermore, the expression level of all tested miRNAs which belong to the same precursor was compared in latent CMV infected group (Fig. 2). Stark et al., found differential incorporation of the 5p and 3p forms of miR-UL112 at 24 hpi (hours post infection) [18]. Correlation analysis of these two miRNAs shows that although these two molecules are derived from one precursor, each can be expressed in different rates due to the infection condition of the target cells. It was previously demonstrated that CMV miRNA precursors incorporate their individual arms into Ago1 and Ago2 differentially [18]. These results show that although miRNAs that has one precursor arise from the same origin but some of them has different expression rate during inactivation of CMV in patients and in this study miR-UL22A-3p/5p, miR-US25-1-3p/5p, and miR-US25-2-3p/5p had significant co-expression pattern in latent CMV infected group.

Additionally, the expression level of all tested miRNAs which belong to the same precursor was compared in active CMV infected group (Fig. 3). These results show that although microRNAs that has the same precursor, arise from the same origin but some of them has different expression rate during activation of CMV in patients and in the current study, miR-UL112-3p/5p,
miR-UL112-3p, and miR-US25-2-3p, miR-UL36-3p and miR-UL70-3p show significant difference between patient groups (Fig. 4).

The expression level of CMV-miRNAs, were compared to the BUN/Creatinine level of latent CMV infected group and the results showed that only miR-UL36-3p with BUN level and miR-UL112-5p and miR-US25-1-5p with Creatinine level had a statistically significant relation in the patients with latent CMV grade. Additionally,
the same study in the active CMV infected group determined that miR-UL112-5p, miR-US25-2-3p and -5p, miR-UL36-3p and -5p and miR-UL70 with the BUN level and all tested miRNAs except miR-US25-1-3p, miR-UL148D and miR-UL36-3p had a significant relation with Creatinine level in the patients with active CMV grade. Additionally, the data related to patient condition and BUN/Creatinine level of them are summarized in Tables 1 and 2.

Discussion

Earlier, the encoded miRNAs by CMV were detected steadily in host circulating blood. Further studies confirmed the relation between changes in circulating CMV encoded miRNA contents and pathological outcomes in different diseases such as hypertension, cardiovascular disease, cancer, and diabetes, psychiatric and neurological diseases. It is believed that dysregulated viral miRNAs can alter the host transcriptome [19]. The relation between circulating miRNAs of CMV and human diseases was confirmed in essential hypertension for the first time [20]. Reactivation of CMV infection might happen and can cause serious and life-threatening problems in patients harboring impaired or immature immune systems like transplant recipients [21, 22]. miRNAs can promote controlling of viral replication in CMV seropositive SOT recipients’ post-transplantation [23]. In current study, the de novo expression of CMV miRNAs during activation and inactivation in KTRs is estimated.

In vitro studies have been confirmed the inhibitory role of CMV miRNAs (US25-1, US25-2-5p, US25-2-3p, and UL112-3p) on the viral replication in the absence of immunosuppression [24, 25]. Therefore, inverse correlations between viral load (DNAmía) and the expression level of miRNAs were expected. Our finding (data not shown) and others [26] could not certify this correlation and proved an association between viral miRNA level and the chance of CMV viremia recurrence after primary treatment, signifies a potential immunoregulatory role for CMV miRNAs. In current study, we found that most of studied viral miRNAs (except for miR-US25-1-3p and UL148D) were increased in the active CMV infected KTRs which is consistent with studies that evaluated the expression of CMV miRNAs in vitro during lytic infection [26]. These results show that the expression level of all studied viral miRNAs except for miR-US25-1-3p and...
UL148D, have a positive correlation with the increase in the viremia during active CMV infection. Additionally, a study on SOT pre-transplant samples, clarified that expression of some of the host miRNAs (miR-200b-3p and miR-200c-3p) in CMV seropositive patients is correlated to elevation of CMV viremia post-transplantation. The researchers believe that in order to gain the ability of controlling CMV replication post-transplantation, the miRNA responses should be clearly studied [23].

The up-regulation of miR-UL112 that have been confirmed in our study and formerly found in some diseases such as essential hypertension [20], Type 2 diabetes, glioblastoma [15], and SOT patients [26], candidate this CMV miRNA as a novel biomarker for discriminating between CMV latency and active replication in various infected patients [19]. Different targets of miR-UL112-3p (reviewed in Additional file 1: Table S3), miR-UL112-5p (such as caspase 3 and ERAP) [21, 27], miR-UL22A-3p and miR-UL22A-5p (caspase 3 and 7) that are mostly related to production of apoptosis [28].

miR-UL22A induce viral recurrence through down regulation of SMAD3, which is essential in maintenance of latency in infected HPCs (hematopoietic progenitor cells) [29]. Lisboa et al. also, confirmed that miR-UL22A targets C-MYC and results in repression of the heat-shock proteins to support CMV recurrent viremia in SOT patients, propose a new mechanism of immune modulation that help in understanding CMV pathogenesis and might be a candidate biomarker for clinical diagnosis post-transplantation after further evaluations [26].

Our result showed that the expression of miR-UL22A-3p/5p in KT patients upregulates in active CMV infected group. It was interesting that the expression of CMV miR-UL22A-3p in latent CMV infected group was even less than the control group. There are limited studies analyzing the function of CMV miR-UL22A-3p/5p, but it seems that these two miRNAs are managed to establish recurrence of viral infection [30].

CMV miR-US25-1, and miR-US25-2, possibly target cellular genes that might render to viral titer changes [25]. Up-regulation of miR-US25-1-5p, miR-US-25-2-3p, and miR-US-25-2-5p have been verified in SOT patients [26]. Other studies and also ours, indicate that probably miR-US25-1-3p has a slight role in early latent phase expression in order to keep this situation stable, but miR-US25-1-5p might have roles in later expression during activation of viral lytic phase again for reaching a stable latent condition through blocking cell cycle progression.

**Fig. 3** Comparing the correlation between viral precursor miRNAs gene expression in active CMV infected group, miRNAs that has one precursor arise from the same origin but some of them has different expression rate during activation of CMV.
by modulating different molecules such as cyclins [27]. CDK6 that is a molecule involved in initiation and maintenance of cell cycle exit during differentiation, and prevents cell proliferation [27] and three groups of genes in association with cell cycle control (including cyclin E1 and E2), as well as histone proteins, and tumor progression are targets of miR-US25-1-3p and -5p, respectively [31].

It was clearly found that over-expression of miR-US25-2-3p results a reduction in CMV replication. miR-US25-2-3p targets eIF4A1 (eukaryotic translation initiation factor 4A1), a vital molecule for cap-dependent translation, cell proliferation and viral growth [24] as well as FAS (a member of apoptosis pathway), CDK6, and CASP3 [27]. By noticing the role of targets of miR-US25-2-3p in reduction of CMV replication and also, by considering

![Fig. 4 The ROC curve analyses of CMV miRNAs between latent and active CMV infected groups](image-url)
the results of our study, it seems that it has a significant role in resuming latency after activation of the virus. Furthermore, the expression rate of CMV miR-US25-2-3p/5p during viral inactivation and activation is different which in latent phase their expression rate is significantly the same while in active duration is not.

Some of the miR-UL148D cellular targets are RANTES (CCL5; that was experimentally confirmed during CMV lytic infection) [32], IEX-1 (suppressed by miR-UL148D and cause inhibition in apoptosis of target cells) [33], IER5 (which can establish latency via increasing CDC25B expression, and limit IE gene expression) [34], ACVR1B (Activin A receptor 1B; is also another target for miR-UL148D during latency and is a part of the activin A signaling cascade) [35]. Previously it was showed that miR-UL148D up-regulates in chronic hepatitis B [36] and Oral lichen planus [37]. Collectively, the data and our results suggest that CMV miR-UL148D function is related to stable latency situation especially during CMV latent infection rather than lytic [38].

CDK6 and FAS are proved targets for miR-UL36-3p and in this way, it can inhibit apoptosis in target cells [27]. Furthermore, one study presented that miR-UL36-3p has role in promoting efficient lytic replication by down regulating expression of the latency associated protein UL138 and ectopic expression of miR-UL36 enhanced CMV DNA synthesis during the early stages of replication in fibroblasts [39]. SLC25A6 (ANT3) is a western blot proved target for miR-UL36-5p which can cause inhibition in apoptosis pathway [40].

A study found that during early stages of antiviral therapy in SOT patients, increase in the level of miR-UL36-5p is related to the longer persistence of viremia although in in vitro models this miRNA was detected to increase

### Table 1 The detailed condition of selected active CMV infected patients

| Number of patients | CMV-DNA viral load (copy number/ml) | Type of transplant | CMV serostatus | Transplant history | BUN (mg/dL) | Creatinine (mg/dL) |
|--------------------|-----------------------------------|------------------|----------------|-------------------|------------|-------------------|
| 1                  | 170,000                           | Whole            | D+/-/R—        | No                | 30.0       | 4.00              |
| 2                  | 52,000                            | Whole            | D+/-/R—        | No                | 26.0       | 3.20              |
| 3                  | 138,000                           | Whole            | D+/-/R—        | No                | 28.5       | 3.80              |
| 4                  | 1,250,000                         | Whole            | D+/-/R—        | No                | 32.8       | 4.50              |
| 5                  | 800,000                           | Whole            | D+/-/R—        | No                | 25.0       | 2.10              |
| 6                  | 13,000                            | Whole            | D—/-/R—        | No                | 21.0       | 2.70              |
| 7                  | 150,000                           | Whole            | D+/-/R—        | No                | 26.5       | 3.10              |
| 8                  | 45,000                            | Whole            | D+/-/R—        | No                | 21.8       | 1.80              |
| 9                  | 780,000                           | Whole            | D—/-/R—        | No                | 19.8       | 2.60              |
| 10                 | 350,000                           | Whole            | D+/-/R+        | Yes               | 26.5       | 3.50              |
| 11                 | 42,000                            | Whole            | D+/-/R—        | No                | 15.7       | 1.40              |
| 12                 | 65,000                            | Whole            | D—/-/R+        | No                | 12.9       | 1.80              |
| 13                 | 660,000                           | Partial          | D+/-/R+        | No                | 30.8       | 4.40              |
| 14                 | 32,000                            | Whole            | D+/-/R—        | Yes               | 26.6       | 3.40              |
| 15                 | 14,000                            | Whole            | D+/-/R—        | Yes               | 17.1       | 1.90              |
| 16                 | 20,500                            | Whole            | D+/-/R—        | No                | 18.2       | 1.50              |
| 17                 | 105,000                           | Whole            | D—/-/R+        | No                | 24.8       | 2.98              |
| 18                 | 120,000                           | Partial          | D—/-/R+        | No                | 24.8       | 2.91              |
| 19                 | 22,500                            | Whole            | D+/-/R—        | No                | 19.1       | 1.60              |
| 20                 | 14,500                            | Whole            | D+/-/R—        | No                | 19.2       | 1.85              |
| 21                 | 17,500                            | Whole            | D+/-/R—        | No                | 20.8       | 2.80              |
| 22                 | 41,000                            | Whole            | D+/-/R—        | No                | 14.5       | 1.90              |
| 23                 | 27,000                            | Whole            | D+/-/R—        | No                | 16.1       | 2.10              |
| 24                 | 55,000                            | Whole            | D+/-/R—        | No                | 11.5       | 2.90              |
| 25                 | 75,000                            | Whole            | D+/-/R—        | No                | 10.9       | 1.10              |
| 26                 | 85,000                            | Whole            | D+/-/R—        | No                | 24.8       | 1.00              |
| 27                 | 20,000,000                        | Whole            | D+/-/R+        | No                | 22.1       | 1.90              |
| 28                 | 135,000                           | Partial          | D—/-/R+        | No                | 33.4       | 4.20              |
| 29                 | 230,000                           | Whole            | D—/-/R+        | No                | 18.5       | 2.10              |
| 30                 | 750,000                           | Whole            | D+/-/R—        | No                | 12.5       | 1.70              |
viral replication. The authors also proposed that the mentioned effect might be the result of other opposing forces such as therapeutic immune suppression [15]. Our data also showed that both miR-UL36-3p/5p are significantly increased in active phase of CMV infection.

There are different reports about finding miR-UL70. Stark et al. [18] small RNA-seq data did not support expression of miR-UL70, despite the quantitative PCR experiments by Stern-Ginossar et al. [25] could detect this miRNA. But, Pfeffer et al. [9] also failed to detect this particular miRNA in their cloning efforts. Although some studies were failed in estimating the expression of miR-UL70-3p, Shen et al. [12], evaluated the production of miR-UL70-3p in different cell types and verified the inducing role of this miRNA in CMV replication. In our study we also revealed that the expression of this viral miRNA is significantly increased in active CMV infected KTRs and its importance in maintenance of the viral replication.

| Number of patients | CMV-DNA viral load | Type of transplant | CMV serostatus | Transplant history | BUN (mg/dL) | Creatinine (mg/dL) |
|--------------------|--------------------|-------------------|----------------|--------------------|-------------|-------------------|
| 1                  | Negative           | Whole             | D+/R−          | No                 | 56.0        | 5.10              |
| 2                  | Negative           | Whole             | D+/R−          | No                 | 7.1         | 2.50              |
| 3                  | Negative           | Whole             | D+/R−          | No                 | 20.9        | 3.10              |
| 4                  | Negative           | Partial           | D+/R−          | No                 | 31.5        | 3.80              |
| 5                  | Negative           | Whole             | D+/R−          | No                 | 21.5        | 4.00              |
| 6                  | Negative           | Whole             | D−/R−          | No                 | 19.8        | 4.60              |
| 7                  | Negative           | Whole             | D+/R−          | No                 | 27.9        | 2.40              |
| 8                  | Negative           | Whole             | D−/R−          | No                 | 14.5        | 1.40              |
| 9                  | Negative           | Whole             | D−/R−          | No                 | 20.9        | 1.90              |
| 10                 | Negative           | Whole             | D+/R+          | No                 | 23.4        | 2.80              |
| 11                 | Negative           | Whole             | D+/R+          | No                 | 14.8        | 1.70              |
| 12                 | Negative           | Whole             | D−/R−          | No                 | 10.9        | 2.50              |
| 13                 | Negative           | Whole             | D+/R+          | No                 | 28.2        | 3.70              |
| 14                 | Negative           | Whole             | D−/R+          | No                 | 26.6        | 2.70              |
| 15                 | Negative           | Whole             | D+/R−          | No                 | 18.9        | 1.20              |
| 16                 | Negative           | Whole             | D+/R−          | No                 | 17.9        | 1.80              |
| 17                 | Negative           | Whole             | D−/R−          | No                 | 29.7        | 2.28              |
| 18                 | Negative           | Whole             | D−/R−          | No                 | 23.1        | 2.21              |
| 19                 | Negative           | Whole             | D+/R−          | No                 | 18.2        | 1.90              |
| 20                 | Negative           | Whole             | D+/R−          | No                 | 17.2        | 1.15              |
| 21                 | Negative           | Whole             | D+/R+          | No                 | 20.8        | 2.10              |
| 22                 | Negative           | Whole             | D+/R−          | No                 | 14.5        | 1.20              |
| 23                 | Negative           | Whole             | D+/R−          | No                 | 19.8        | 1.40              |
| 24                 | Negative           | Whole             | D−/R−          | No                 | 15.9        | 2.20              |
| 25                 | Negative           | Whole             | D+/R−          | No                 | 11.7        | 1.40              |
| 26                 | Negative           | Whole             | D+/R−          | No                 | 28.1        | 1.70              |
| 27                 | Negative           | Whole             | D+/R+          | No                 | 20.9        | 1.20              |
| 28                 | Negative           | Partial           | D−/R−          | No                 | 25.5        | 3.50              |
| 29                 | Negative           | Whole             | D+/R−          | No                 | 18.5        | 1.40              |
| 30                 | Negative           | Whole             | D+/R−          | No                 | 13.8        | 1.00              |
| 31                 | Negative           | Whole             | D+/R−          | No                 | 56.0        | 5.10              |
There were some limitations in our study which it should be into consideration in further studies. We separated buffy coat and plasma of samples but as this was a preliminary report monocytes and dendritic cells weren’t separated and studying these results separately will help us in better understanding the expression pattern of CMV miRNAs during latent and lytic conditions.

Conclusion
As a matter of fact, the role of miRNAs is detected in both lytic and latent phases of CMV infection. Consequently, in the present study, an extremely high expression level of miR-UL112-3p, -UL112-5p, -UL22A-3p, -UL22A-5p, -US25-1-5p, -US25-2-5p, -UL36-3p, -UL36-5p and -UL70-3p detected in the active CMV infected KTRs in comparison to latent ones, which prove their possible critical and central biological role in the CMV pathogenesis. Finally, it should be considered that the significant changes in viral miRNAs in active vs. latent CMV infected KTRs seems to be of immense importance for further evaluations.

Abbreviations
CMV: Human cytomegalovirus; KTRs: Kidney transplant recipients; miRNAs, miRs: MicroRNAs; NK: Natural killer; MICB: Major histocompatibility complex class I-related chain B; pri-miRs: Primary miRs; eIF4A1: Eukaryotic translation initiation factor 4A1; ACVR1B: Activin A receptor 1B.

Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s12985-022-01880-5.

Author contributions
AA performed the majority of collecting and writing of the data; AA, RY and MG performed the molecular investigations; AA, RY and MG designed and coordinated the research; AA, RY wrote the paper. All authors read and approved the final manuscript.

Funding
This study was supported by Shiraz University of medical sciences (Grant No. 8581). Funding sources had no influence over study design, data collection, analysis or interpretation or manuscript preparation and submission.

Availability of data and materials
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Declarations
Ethics approval and consent to participate
All applied protocols in this study, were in complete agreement with the Helsinki Declaration and its later amendment. The local Ethics committee of Shiraz University of Medical Sciences approved every step of this study. After explaining the study objectives, written informed consent was obtained from each patient.

Consent for publication
Written informed consent for publication was obtained.

Competing interests
The authors declare that they have no competing interests.

Author details
1 Shiraz Nephro-Urology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran. 2 Shiraz Transplant Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.

Received: 13 April 2022 Accepted: 8 September 2022

References
1. Ramanan P, Razonable RR. Cytomegalovirus infections in solid organ transplantation: a review. Infect Chemother. 2013;45:260–71. https://doi.org/10.3947/ic.2013.45.3.260.
2. Azevedo LS, Pierrotti LC, Abdala E, Costa SF, Strabelli TMV, Campos SV, et al. Cytomegalovirus infection in transplant recipients. Clinics. 2015;70:515–23. https://doi.org/10.6061/clinics/2015(07)09.
3. De Keyzer K, Van Laecke S, Peeters P, Vanholder R. Human cytomegalovirus and kidney transplantation: a clinician’s update. Am J Kidney Dis. 2011;58:118–26. https://doi.org/10.1053/j.ajkd.2011.04.010.
4. Andrews PA, Emery VC, Newstead C. Summary of the British transplantation society guidelines for the prevention and management of CMV disease after solid organ transplantation. Transplantation. 2011;92:1181–7. https://doi.org/10.1097/TPB.0b013e318235c7fc.
5. Dunn W, Trang P, Zhong Q, Yang E, van Belle C, Liu F. Human cytomegalovirus expresses novel microRNAs during productive viral infection. Cell Microbiol. 2005;7:1684–95. https://doi.org/10.1111/j.1462-5822.2005.00598.x.
6. Grey F, Meyers H, White EA, Spector DH, Nelson J. A human cytomegalovirus-encoded microRNA regulates expression of multiple viral genes involved in replication. PLoS Pathog. 2007;3:1593–602. https://doi.org/10.1371/journal.ppat.0030163.
7. Afshari A, Yaghobi R, Rezaei G. Inter-regulatory role of microRNAs in interaction between viruses and stem cells. World J Stem Cells. 2021;13:985.
8. Mocarski ES, Immune escape and exploitation strategies of cytomegalovirus: Impact on and imitation of the major histocompatibility system. Cell Microbiol. 2004;6:707–17. https://doi.org/10.1111/j.1462-5822.2004.00425.x.
9. Pfeffer S, Sewer A, Lagos-Quintana M, Sheridan R, Sander C, Grässer FA, et al. Identification of microRNAs of the herpesvirus family. Nat Methods. 2005;2:269–76. https://doi.org/10.1038/nmeth746.
10. Cullen BR. Viruses and micrornas. Nat Genet. 2006;38:525-30. https://doi.org/10.1038/ng1793.
11. Gottwein E, Cullen BR. Viral and cellular microRNAs as determinants of viral pathogenesis and immunity. Cell Host Microbe. 2008;3:375–87. https://doi.org/10.1016/j.chom.2008.05.002.
12. Shen ZZ, Pan X, Miao LF, Ye HQ, Chavanas S, Davrinche C, et al. Comprehensive analysis of human cytomegalovirus microRNA expression during lytic and quiescent infection. PLoS ONE. 2014. https://doi.org/10.1371/journal.pone.0088531.
13. Powdrill MH, Desrochers GF, Singaravelu R, Pezacki JP. The role of microRNAs in metabolic interactions between viruses and their hosts. Curr Open Virol. 2016;19:71–6. https://doi.org/10.1007/j.coviro.2016.07.005.
14. Shen K, Xu L, Chen D, Tang W, Huang Y. Human cytomegalovirus-encoded miR-UL112 contributes to HCMV-mediated vascular diseases by inducing vascular endothelial cell dysfunction. Virus Genes. 2018;54:172–81. https://doi.org/10.1007/s11262-018-1532-9.

15. Mohammad AA, Rahbar A, Lui WD, Davoudi B, Catrina A, Straiglott G, et al. Detection of circulating hcmv-miR-UL112-3p in patients with glio-blastoma, rheumatoid arthritis, diabetes mellitus and healthy controls. PLoS ONE. 2014. https://doi.org/10.1371/journal.pone.0113740.

16. Fernández-Moreno R, Torre-Cisneros J, Cantisán S. Human cytomegalovirus (HCMV)-encoded microRNAs: potential biomarkers and clinical applications. RNA Biol. 2021;18:2194–202. https://doi.org/10.1080/15472826.2021.1930757.FORMAT/EPUB.

17. Patro ARK. Subversion of immune response by human cytomegalovirus. Front Immunol. 2019;10:1155. https://doi.org/10.3389/fimmu.2019.01155.BIREXT.

18. Stark Tj, Arnold JD, Spector DH, Yeo GW. High-resolution profiling and analysis of viral and host small RNAs during human cytomegalovirus infection. Cell Host Microbe. 2020;27:104. https://doi.org/10.1016/j.chom.2015.05.014.

19. Wang C, Wang J-J, Zhang C. Altered human cytomegalovirus-encoded miRNAs in host circulation: novel disease biomarkers and potential aetiological agents. ExRNA. 2019;1:1–13. https://doi.org/10.1186/S41544-019-0029-6.

20. Li S, Zhu J, Zhang W, Chen Y, Zhang K, Popescu LM, et al. Signature microRNA expression profile of essential hypertension and its novel link to human cytomegalovirus infection. Circulation. 2011;124:175–84. https://doi.org/10.1161/CIRCULATIONAHA.110.12237.

21. Requiao-Moura LR, deMatos ACC, Pacheco-Silva A. Cytomegalovirus infection in renal transplantation: clinical aspects, management and the perspectives. Einstein (São Paulo, Brazil). 2015;13:142–8. https://doi.org/10.1590/1679-45082015SRN3175.

22. Afshari A, Yaghobi R, Karimi MH, Azarpira N, Geramizadeh B, Darbouy M, et al. Association between interleukin-21, 23 and 27 expression and protein level with cytomegalovirus infection in liver transplant recipients. Int J Organ Transplant Med. 2020;11:27–34.

23. Han Sh, Kumar D, Ferreira VH, Egli A, Hirsch HH, Weisser M, et al. Human microRNA responses predict cytomegalovirus replication following solid organ transplantation. 2017;213:537–83. https://doi.org/10.1093/infdis/jjw596.

24. Qi M, Qi Y, Ma Y, He R, Ji Y, Sun Z, et al. Over-expression of human cytomegalovirus miR-US52-2-3p downregulates eIF4A1 and inhibits HCMV replication. FEBS Lett. 2013;587:2266–71. https://doi.org/10.1016/j.febslet.2013.05.057.

25. Stern-Gnossar N, Saleh N, Goldberg MD, Prichard M, Wolf DG, Mandelboim O. Analysis of human cytomegalovirus-encoded microRNA activity during infection. J Virol. 2009;83:10684–93. https://doi.org/10.1128/jvi.01292-09.

26. Lisaboa LF, Egli A, O’Shea D, Åberg A, Hartmann A, Rollag H, et al. Hcmv-miR-UL22A-5p: a biomarker in transplantation with broad impact on host gene expression and potential immunological implications. Am J Transplant. 2015;15:1893–902. https://doi.org/10.1111/ajt.13222.

27. Kim S, Seo D, Kim D, Hong Y, Chang H, Baek D, et al. Temporal landscape of microRNA-mediated host-virus crosstalk during productive human cytomegalovirus infection. Cell Host Microbe. 2015;17:838–51. https://doi.org/10.1016/j.chom.2015.05.014.

28. Skaletskaya A, Bartle LM, Chittenden T, McCormick AL, Mocarki ES, Goldmacher VS. A cytomegalovirus-encoded inhibitor of apoptosis that suppresses caspase-8 activation. Proc Natl Acad Sci. 2001;98:7629–34. https://doi.org/10.1073/PNAS.141108798.

29. Hancock MH, Crawford LB, Pham AH, Mitchell J, Struthers HM, Yurochko AD, et al. Human cytomegalovirus miRNAs regulate TGF-β to mediate myelosuppression while maintaining viral latency in CD34+ hematopoietic progenitor cells. Cell Host Microbe. 2020;27:104. https://doi.org/10.1016/J.CHOM.2019.11.013.

30. Lau B, Poole E, Krishna B, Sellant I, Wills MR, Murphy E, et al. The expression of human cytomegalovirus microRNA MIR-UL148D during latent infection in primary myeloid cells inhibits activin-a-triggered secretion of IL-6. Sci Rep. 2016. https://doi.org/10.1038/srep31205.

31. Grei F, Tirabassi R, Meyers H, Wu G, McWeeney S, Hook L, et al. A viral microRNA down-regulates multiple cell cycle genes through mRNA 5’UTRs. PLoS Pathog. 2010. https://doi.org/10.1371/journal.ppat.1000967.

32. Kim Y, Lee S, Kim S, Kim D, Ahn JH, Ahn K. Human cytomegalovirus clinical strain-specific microRNA MIR-UL148D targets the human chemokine RANTES during infection. PLoS Pathog. 2012. https://doi.org/10.1371/journal.ppat.1002577.

33. Wang FP, Qi Y, Huang YJ, Qi ML, Ma YP, He R, et al. Identification of immediate early gene X-1 as a cellular target gene of hcmv-miR-UL148D. Int J Mol Med. 2013;31:959–66. https://doi.org/10.3892/ijmm.2013.1271.

34. Pan C, Zhu D, Wang Y, Li L, Li D, Liu F, et al. Human cytomegalovirus miR-UL148D facilitates latent viral infection by targeting host cell immediate early response gene S. PLoS Pathog. 2016. https://doi.org/10.1371/journal.ppat.1006607.

35. Loomans HA, Andl CD, Andl CD, Andl CD, Andl CD, Andl CD, Andl CD. Intertwinning of activin a and TGFβ signaling: Dual roles in cancer progression and cancer cell invasion. Cancers (Basel). 2014;7:70–91. https://doi.org/10.3390/cancers7010070.

36. Pan Y, Wang N, Zhou Z, Liang H, Pan C, Zhu D, et al. Circulating human cytomegalovirus-encoded HCMV-miR-US4-1 as an indicator for predicting the efficacy of IFNα treatment in chronic hepatitis B patients. Sci Rep. 2016. https://doi.org/10.1038/srep23007.

37. Ding M, Wang X, Wang C, Liu X, Zen K, Wang W, et al. Distinct expression profile of HCMV encoded miRNAs in plasma from oral lichen planus patients. J Transl Med. 2017;15:1–12. https://doi.org/10.1186/s12967-017-1222-8FIGURES/5.

38. Golshan M, Yaghobi R, Geramizadeh B, Afshari A, Roozbesh J, Malek-Hosseinia SA. Importance of miR-UL148D expression pattern in cytomegalovirus infected transplant patients. Int J Organ Transplant Med. 2021;12:46–54.

39. Huang Y, Sun Z, Ruan Q. Down-regulation of human cytomegalovirus UL138, a novel latency-associated determinant, by hcmv-miR-UL36. J Mol Med. 2013. https://doi.org/10.1007/s00109-013-1016-0.

40. Guo X, Huang Y, Qi Y, Qi Y, Liu Z, Ma Y, Shao Y, et al. Human cytomegalovirus miR-UL36-Sp inhibits apoptosis via downregulation of adenosine nucleotide translocator 3 in cultured cells. Adv Virol. 2015,160:2483–90. https://doi.org/10.1007/s12977-015-2498-8.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.